亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

作者
Max Joseph Korman,Torbjørn Fosen Wisløff
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy [Oxford University Press]
卷期号:4 (1): 15-22 被引量:68
标识
DOI:10.1093/ehjcvp/pvx010
摘要

Aims: Despite the success of statins, there remains unmet clinical need in cardiovascular disease (CVD) prevention. New proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) by 55-65%. Two PCSK9 inhibitors, evolocumab, and alirocumab, were approved for use in Norway but not yet for reimbursement through public national insurance. We aim to explore the cost-effectiveness of these compared with available treatments in a Norwegian setting. Methods and results: A state transition Markov model was developed to model the cost-effectiveness of PCSK9 inhibitors for prevention of coronary heart disease, ischaemic strokes, and death among high-risk patient subpopulations in Norway, in both primary and secondary settings. Evolocumab and alirocumab are compared against ezetimibe and standard treatment. Risk of CVD is based on population incidence rates and adjusted according to baseline risk factors. Preventative effect of treatment was modelled according to absolute reduction in LDL-C. PCSK9 inhibitors were never found to be cost-effective in primary prevention. In secondary prevention they were cost-effective only for older, high-risk patients. The lowest cost-effectiveness ratios were for heterozygous familial hypercholesterolaemia patients and high-risk diabetics, with €63 200 and €68 400 per quality-adjusted life-year, respectively. Conclusion: High lifetime costs of PCSK9 inhibitors may not be offset by estimated health gains for most eligible patients. PCSK9 inhibitors are found in the model only to be cost-effective in secondary prevention for older patients with high absolute risk of CVD. This picture is likely to change as price decreases. Future research is needed to determine the long-term preventative effects of PCSK9 inhibitors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
7秒前
Ccccn完成签到,获得积分10
10秒前
落润晓发布了新的文献求助10
11秒前
agathahqs的应助被初景采纳,获得10
12秒前
15秒前
超级的愫完成签到,获得积分10
15秒前
17秒前
35秒前
45秒前
不安雅霜完成签到,获得积分10
50秒前
51秒前
DR_MING完成签到,获得积分10
51秒前
DR_MING发布了新的文献求助10
55秒前
zsmj23完成签到 ,获得积分0
57秒前
1分钟前
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得30
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
Lucas的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
乐乐的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
桃桃发布了新的文献求助10
1分钟前
和谐早晨完成签到,获得积分10
1分钟前
陶醉的美女完成签到,获得积分10
1分钟前
领导范儿的应助被桃桃采纳,获得30
1分钟前
1分钟前
甜美尔烟完成签到,获得积分10
2分钟前
2分钟前
madeleinli完成签到,获得积分10
2分钟前
害羞语薇完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158792
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354